CooperSurgical has acquired ZyMōt Fertility, a subsidiary of DxNow, Inc. Read the full announcement here.

Reproductive Care

Fertility & Birth

Women’s & Family Care

Education & Training

Support & Compliance

Reproductive Care

CooperSurgical offers leading contraception that can help women achieve their goals effectively, safely, and on their own timeline.

Contraception

Preservation

Fertility & Birth

The CooperSurgical® portfolio offers effective solutions that support clinical efficiency and engaged and supported patients. All to conceive, deliver, and protect healthy babies.

Assisted Reproductive Technology

Labor & Delivery

Donor Egg & Sperm

Newborn Stem Cells

Women’s & Family Care

Get faster diagnostic tools and transformative treatment options to keep women healthy and strong.

Wellcare & Diagnostics

See all products

Uterine Health Office Treatments

See all products

Gynecological Surgery

See all products

Specialty Surgery

See all products

Education & Training

Supporting healthcare providers around the world.

Medical Devices

Fertility

Medical Affairs

Support & Compliance

ZyMōt™ Multi Sperm
Separation Device

Contact Us
Hero-Zymot

Sperm preparation made easy

The ZyMōt™ Multi Sperm Separation Device is an innovative and simpler way to isolate high-quality, motile sperm for use in ART procedures, separating sperm with low DNA fragmentation1-4 – helping to increase the chance of a successful fertility treatment cycle.4–7

Product characteristics

Indications for use8
The ZyMōt™ Multi Sperm Separation Device is intended for preparing motile sperm from semen for use in the treatment of infertile couples by intracytoplasmic sperm injection (ICSI), in vitro fertilization (IVF), and intrauterine insemination (IUI) procedures.

Description8
• Manufactured in two processing volumes: 850μL and 3mL
• The primary difference between the devices is the processing volume
• Single-use only

Zymot-point-diagram

Mode of action

Sperm separation using ZyMōt™ allows for high-quality, motile sperm with low DNA fragmentation to pass through the microporous membrane, ready for collection.4,8

Group 24

1

A sperm sample is applied through the device’s inlet port, connected to a lower sample chamber.4,8

2

This chamber is separated from an upper collection chamber by a microporous membrane.4,8
– Medium is overlaid on top of the microporous membrane.8

3

During incubation, the most progressively motile sperm can migrate through the pores into the fresh medium allowing for collection of a motile sperm sample (optimal sperm) from the outlet port.4,8

A unique andrology solution

ZyMōt™ represents a fundamental change in thinking about how to effectively separate high-quality sperm for ART procedures and can provide multiple practical advantages for any lab:1,2,4

Time savings
• Enables processing whenever a sample is ready, eliminating delays caused by an equipment bottleneck4.9
• Only approximately 5 minutes of total hands-on lab technician time per sample required4,8,9

Fewer handling steps per sample, which could help reduce the risk of errors
• A shorter chain of custody involving fewer movements per sample means that the ZyMōt device helps to reduce mismatching risk and thus potential for costly errors3,4

process-graph

Simplifying and standardizing workflow
• The innovative technology helps ensure standardization in sperm preparation, streamlining workflow, and reducing hands-on time, freeing up operators to perform other tasks4
• Minimal training requirements when using the ZyMōt device equate to more flexibility across users with varying levels of experience4

Comprehensive product training
• Top-tier training through an innovative digital simulation program created by LeQuest
• A range of training courses and workshops (from our PECS/CAS team) for professionals in ART, catering to various experience levels and are available both virtually and at global locations

image 2

To learn more about how the ZyMōt™ Multi Sperm Separation Device can help you effectively separate high-quality sperm, contact your ZyMōt LeQuest License Administrator.

Click Here to Contact your ZyMōt LeQuest License Administrator

Clinical Evidence

The ZyMōt device has statistically shown significant improvements in three DNA and stress-focused indicators of sperm health and function.2 Comparison of DNA fragmentation levels for raw semen, as well as after processing with commercially available gradients (with and without swim-up) and the ZyMōt Multi Sperm Separation Device. Figure focusses on the DNA fragmentation indicator, adapted from Broussard (2019).2 ZyMōt helps yield high-quality sperm for assisted reproduction7 Parameters and SDF values in aliquots of specimen processed by density gradient and microfluidics in comparison to raw semen of 23 men. Table adapted from Parrella (2019).7 ZyMōt improved blastocyst formation, utilization, and euploidy rates.10 Mean outcome rates between the different sperm preparation methods for all couples. *Based on study (n=3).
Figure adapted from Banti (2024).10 Using the ZyMōt device has been shown to increase euploid embryos and establish healthy pregnancies for couples with history of previous ART failure.5,7,10–16 Rate of euploidy in blastocysts by sperm preparation method. Figure adapted from Parrella (2019), Anderson (2020), Beyhan (2020), Leisinger (2021), Alhelou (2023), Kocur (2023),
Godiwala (2024), Banti 2024, Paccagnini (2024).5,7,10–16 Graph2-part1.jpg

The ZyMōt device has statistically shown significant improvements in three DNA and stress-focused indicators of sperm health and function.2

Comparison of DNA fragmentation levels for raw semen, as well as after processing with commercially available gradients (with and without swim-up) and the ZyMōt Multi Sperm Separation Device.

Graph2-part1.jpg

Figure focusses on the DNA fragmentation indicator, adapted from Broussard (2019).2

ZyMōt helps yield high-quality sperm for assisted reproduction7

Parameters and SDF values in aliquots of specimen processed by density gradient and microfluidics in comparison to raw semen of 23 men.

Table adapted from Parrella (2019).7

ZyMōt improved blastocyst formation, utilization, and euploidy rates.10

Mean outcome rates between the different sperm preparation methods for all couples.

*Based on study (n=3).
Figure adapted from Banti (2024).10

Using the ZyMōt device has been shown to increase euploid embryos and establish healthy pregnancies for couples with history of previous ART failure.5,7,10–16

Rate of euploidy in blastocysts by sperm preparation method.

Figure adapted from Parrella (2019), Anderson (2020), Beyhan (2020), Leisinger (2021), Alhelou (2023), Kocur (2023),
Godiwala (2024), Banti 2024, Paccagnini (2024).5,7,10–16

Listening to experienced ZyMōt™ users

ZyMōt™ is used in over 1,500 fertility clinics across 60 countries and has been utilized in over 200,000 fertility cycles.

“The ZyMōt™ Multi Sperm Separation Device has been a game-changer to treat patients undergoing an IVF or ICSI treatment in our fertility lab! The improved selection process led to reduced DNA fragmentation and increased progressive motility. Also, the reliable technology and easiness to use allows for extreme flexibility and workflow in the lab, allowing more samples to be treated at the same time.”

Neelke de Munck PhD, Lab Director, Centre for Reproductive Medicine, Brussels IVF.*

*Neelke de Munck is a paid consultant for CooperSurgical, Inc.

Zymot-image-laiddown

ZyMōtTM gives you high-quality sperm with a fast and simple preparation method1-4,9

Contact Us

Product Codes

Product CodeProduct NameProcessing Volume (mL)Pack Size
ZMH0850ZyMōtTM Multi (850μL) Sperm Separation Device850μL10 units per pack
ZMH3000ZyMōtTM Multi (3mL) Sperm Separation Device3mL10 units per pack

Related Content

Zymot-separation-thumbnail

How to quickly and effectively prepare sperm with the ZyMōt™ Sperm Separation Device

Follow a live ZyMōt demonstration and discover how to simplify sperm preparation for use in ART procedures.

Watch
Peer-reviewed-paper-large

Sperm Separation and Selection Techniques to Mitigate Sperm DNA Damage

Read the peer-reviewed review article entitled ‘Sperm Separation and Selection Techniques to Mitigate Sperm DNA Damage’.

Read
Zymot-insights-thumbnail

Expert Insights: ZyMōt™ Sperm Separation Device

Watch the Expert Insights webinar to gain a better understanding of ZyMōt and its applications, methodology and outcomes.

Watch

Frequently asked questions

ZyMōt devices can be used with any sample that contain some motile sperm, even at extremely low concentrations. We see clinics using ZyMōt devices for every eligible patient: from samples with relatively high levels of motility/concentration to severe male factor patient samples.

We do not have data to suggest there is a low or high concentration limit, using the standard IFU procedures.

Yes. When using a frozen sample, follow cryobank instructions on thawing the vial. Dilute the sample 1:1 with wash medium (usually 500µL). Mix gently by tapping the tube/vial and inject 850µL of this diluted sample into the inlet port of the ZyMōt Multi 850µL device in the same manner as a fresh sample. Please see the Instructions For Use (IFU) for more details.8

Yes. ZyMōt devices are not just for samples with average parameters. ZyMōt devices are based on sperm motility, requiring a sample that contains some motile sperm, even at extremely low concentrations.

The vast majority of users select the ZyMōt Multi 850µL Sperm Separation Device. It is simple to adopt, easy to use, and has a robust record of success for multiple sample types.6,7 This device delivers 500µL of separated sperm sample that can be used for IUI, IVF or ICSI procedures.8

We do not have data to support use of ZyMōt for surgically extracted samples. The ZyMōt Multi Sperm Separation Device is based on motility and thus require samples to contain motile sperm – TESE are less likely to meet this requirement.

Yes. Viscous samples can be injected into ZyMōt Multi devices. We encourage users to try and avoid excessive manipulation of samples before use with ZyMōt devices. In extreme cases, viscous samples can be diluted slightly with wash medium using the recommended luer-tipped syringe used to inject the sample into a ZyMōt device.

We do not have data to support allowing the sample to incubate with a chemical such as chymotrypsin.

No. The ZyMot Multi 850uL device was designed and optimized with specific requirements for operation, as stated in the Instructions for Use.8 Evidence shows that beyond 30-minute incubation time, DNA fragmentation levels increase in the separated sample.

No. Samples should not be held in ZyMōt devices longer than the 30-minute incubation time. If a sample cannot be used immediately after the 30-minute incubation is complete, remove the sample from the device according to the IFU and store it in an appropriate culture tube, rather than holding the sample in the device.8

If semen sample volume is less than the required 850µL, add medium to the sample to bring the total volume to 850µL, mix gently by tapping the container, and then inject the 850µL solution volume into the device as described in the IFU.8 Injecting 850µL ensures that the lower chamber is full, giving sperm the maximum exposure to the device’s membrane filter, ensuring optimal recovery.

No. Only one ZyMōt Multi 850µL or 3mL device is needed per patient. Each sample will be different, of course, and some patients may not have a suitable concentration for IUI use. Contact your local CooperSurgical representative directly for more details.

Yes. ZyMōt devices have been evaluated in a growing list of peer-reviewed publications. Additional research is ongoing. Contact your local CooperSurgical representative directly for more details.

Yes. ZyMōt devices were FDA cleared in 2018 and CE-MDR certified in 2024.

No. Patients cannot purchase ZyMōt devices directly – they must be obtained through a healthcare provider. Contact us to learn about global organizations currently using ZyMōt devices.  CooperSurgical is happy to provide specific, patient-focused materials to easily and effectively explain how ZyMōt devices can directly benefit a patient’s upcoming procedure.

ZyMōt devices do not require the use of a specific sperm wash medium. Incubation conditions must be appropriate for the type of medium being used.  If using a HEPES/MOPS-buffered medium, ZyMōt devices must be incubated in a 37° C, non-gassed incubator. If using a bicarbonate-buffered medium, ZyMōt devices must be incubated in a 37° C, gassed incubator.8

Yes. ZyMōt devices must be incubated at a 37° C for 30 minutes.8

If sperm have a smaller head size than the membrane pore size, then this can occur.

We do not have any data to indicate that ZyMōt Sperm Separation Device removes viruses or bacteria from a sample.

No. The ZyMōt device is made with certified sperm-safe materials, including the membrane filter. The device and membrane filter contain no drug or chemical treatment.8

The ZyMōt device was originally marketed under other names such as “Chipbaby, Fertile, Fertile Plus, Fertile Ultimate, ZyMōt Fertility”, prior to change in ownership in 2018.  Manufacturing was moved to the United States, when Fertile was then rebranded as ZyMōt. This change ensured a more consistent and precise device with an ability to increase ZyMōt availability across the global marketplace.

In 2024, CooperSurgical acquired ZyMōt Fertility, Inc.

Laboratories are unlikely to have to modify their specific protocols both before and after using ZyMōt, avoiding any potential disruptions to any current andrology-based protocols.4 In addition, there is likely no need for users to order new components that are not readily available and currently stocked. 

a.  All that is required to use ZyMōt, other than the device itself, are:8

i. Fresh or frozen semen sample
ii. 3 x luer-slip tipped syringes
iii. 750µL of medium for the Multi 850µL device / 2.5mL of medium for the Multi 3mL device
iv. 90mm Petri dish
v. Incubator at 37° C
vi. Potentially a capped tube to store the ZyMōt-separated sperm for use later, if necessary


Due to the direct and standardized nature involved, ZyMōt training is minimal and easy for users of various with skills and experience.4

CooperSurgical offers training options in addition to the ZyMōt IFU, including the digital simulation program powered by LeQuest, support from the Clinical Applications Scientist (CAS) team, and general support from the CooperSurgical team, in addition to that of experienced ZyMōt users.

Contact your local CooperSurgical representative directly for more details.

Contact your local CooperSurgical representative directly for more information.

IFU, Instructions For Use; IUI, Intrauterine Insemination; TESE, Testicular Sperm Extraction Samples.

References

  1. Bastuba, M., et al. (2020) Microfluidic sperm separation device dramatically lowers DFI. Fertil Steril. 113(4); e44.
  2. Broussard, A., et al. (2019) Sperm DNA fragmentation (SDF) was most effectively improved by a sperm separation device compared to different gradient and swimup methods. Fertil Steril. 111(4);e15.
  3. Ogbejesi, et al. (2022) Microfluidic sperm sorting compared with traditional density gradient centrifugation: a cost analysis. Fertil Steril. 118(4);e142.
  4. Asghar, W., et al. (2014) Selection of functional human sperm with higher DNA integrity and fewer reactive oxygen species. Adv Healthc Mater. 3(10):1671–9.
  5. Kocur, O., et al. (2023) Can a sperm selection technique improve embryo ploidy? Andrology, 11:1605–1612.
  6. Gode, F., et al. (2019) Comparison of microfluid sperm sorting chip and density gradient methods for use in intrauterine insemination cycles. Fertil Steril. 112:842–848.e1.
  7. Parrella, A., et all. (2019). A treatment approach for couples with disrupted sperm DNA integrity and recurrent ART failure. J Assist Reprod Genet. 36:2057–2066.
  8. ZyMōt™ Instructions For Use.
  9. Adolfsson E, et al. (2024) Clinical validation and experiences of the microfluidics sperm preparation device ZyMot™. Reprod BioMed Online. 48: Suppl 1;103995.
  10. Banti M, et al. (2024) Sperm preparation 10ith microfluidic sperm sorting chip may improve intracytoplasmic sperm injection outcomes compared to density gradient centrifugation. Reprod Sci. 31:1695–1704.
  11. Anderson A, et al. (2020) Euploidy rates and pregnancy outcomes using the ZyMōt™ device for sperm preparation. Fertil Steril. 114:e43-e44.
  12. Beyhan, et al. (2020) Microfluidic device-based semen preparation influences euploidy rates of human blastocysts. Fertil Steril. P-28,E127.
  13. Leisinger CA, et al. Effect of microfluidic sperm separation vs. standard sperm washing processes on laboratory outcomes and clinical pregnancy rates in an unselected patient population. Reproductive Medicine. 2021; 2(3):125-130.
  14. Alhelou, Y, et al. Higher euploidy rate in embryos generated by ICSI using sperm obtained after microfluidics sperm sorting (MFSS). A randomised controlled trial. Fertility & Reproduction. 2023, 5, 418.
  15. Godiwala, P. et al. (2024). The impact of microfluidics sperm processing on blastocyst euploidy rates compared with density gradient centrifugation: a sibling oocyte double-blinded prospective randomized clinical trial. Fertility and Sterility, 122(1), pp.85–94.
  16. Paccagnini, et al. (2024) The role of sperm selection in improving embryo euploidy rate: a comparison between Swim-up and Microfluidic Sperm Selection. Human Reproduction, Volume 39, Issue Supplement_1.
Border-wash

To learn more about how the ZyMōt™ Multi Sperm Separation Device can help you effectively separate high-quality sperm, contact your ZyMōt LeQuest License Administrator.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Name*

Subject to availability. Terms and Conditions apply. By submitting your information and clicking on the ‘Submit’ button you are opting in and thus consenting to being contacted by CooperSurgical, Inc. via email. In addition, you also agree to our Privacy Policy and Terms and Conditions. At any time, you may unsubscribe and opt out of receiving any additional information.